FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Saven

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Treatment Outcome

Anatomy

Lymphocytes

Co-author Network

Publications

TOP 3
Christina A To; Michael M Quigley; Alan Saven; Laura Nicholson
Masquerade without a mass: an unusual cause of severe acute pancreatitis.
Weihsu C Chen; Alan Saven; Darren S Sigal; James C Paulson
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Gregory S Vosganian; Robert W Sharpe; Prabhakar Tripuraneni; Saskia Boisot; William R Freeman; Kathrin I Hartmann; Alan Saven
Primary intraocular lymphoma: a review.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Saven (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christina A To; Michael M Quigley; Alan Saven; Laura Nicholson
Masquerade without a mass: an unusual cause of severe acute pancreatitis.
Journal of gastrointestinal oncology 2013;4(1):114-7.
2012: Weihsu C Chen; Alan Saven; Darren S Sigal; James C Paulson
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Leukemia & lymphoma 2012;53(2):208-10.
2011: Gregory S Vosganian; Robert W Sharpe; Prabhakar Tripuraneni; Saskia Boisot; William R Freeman; Kathrin I Hartmann; Alan Saven
Primary intraocular lymphoma: a review.
Journal of neuro-oncology 2011;105(2):127-34.
2011: Melissa L Torrey; Darren S Sigal; Alan Saven
Development of cladribine at Scripps for hairy cell leukemia and current results.
Leukemia & lymphoma 2011;52 Suppl 2():29-33.
2010: Gregory S Vosganian; Darren S Sigal; Alan Saven
Hairy cell leukemia: current therapies and future directions.
Expert review of hematology 2010;3(6):679-83.
2010: Darren S Sigal; Heather J Miller; Ethan D Schram; Alan Saven
Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Blood 2010;116(16):2884-96.
2010: Weihsu C Chen; Gladys C Completo; Darren S Sigal; Paul R Crocker; Alan Saven; James C Paulson
In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
Blood 2010;115(23):4778-86.
2009: Edward Huynh; Darren Sigal; Alan Saven
Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Leukemia & lymphoma 2009;50 Suppl 1():12-7.
2008: Florent M Martin; Josef T Prchal; Jorge Nieva; Alan Saven; Jeffrey Andrey; Kelly Bethel; James C Barton; Gow Aripally; Sylvia S Bottomley; Jeffrey S Friedman
Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia.
British journal of haematology 2008;143(3):446-50.
2008: Christian A Hassig; Kent T Symons; Xin Guo; Phan-Manh Nguyen; Tami Annable; Paul L Wash; Joseph E Payne; David A Jenkins; Céline Bonnefous; Carol Trotter; Yan Wang; John V Anzola; Elena L Milkova; Timothy Z Hoffman; Sara J Dozier; Brandon M Wiley; Alan Saven; James W Malecha; Robert L Davis; Jerry Muhammad; Andrew K Shiau; Stewart A Noble; Tadimeti S Rao; Nicholas D Smith; Jeffrey H Hager
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Molecular cancer therapeutics 2008;7(5):1054-65.
2008: Darren S Sigal; Alan Saven
Cladribine in indolent non-Hodgkin's lymphoma.
Expert review of anticancer therapy 2008;8(4):535-45.
2008: Paul Timothy Fanta; Alan Saven
Hairy cell leukemia.
Cancer treatment and research 2008;142():193-209.
2007: Jorge Nieva; Alan Saven
Understanding hairy cell leukemia genetics.
Leukemia & lymphoma 2007;48(4):653-4.
2007: Catherine Diamond; Thomas H Taylor; Theresa Im; Mark Wallace; Alan Saven; Hoda Anton-Culver
How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma?
Cancer causes & control : CCC 2007;18(2):135-42.
2006: Kristie A Blum; Jeffrey L Johnson; Donna Niedzwiecki; Lawrence D Piro; Alan Saven; Bruce A Peterson; John C Byrd; Bruce D Cheson
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Cancer 2006;107(12):2817-25.
2006: Michael Nerenberg; Ilona Kariv; Patricia McNeeley; Philippe J Marchand; Sudipto Sur; Jonathan Diver; Samuel Riccitelli; Jorge Nieva; Alan Saven
Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2006;47(10):2194-202.
2006: Rajesh Belani; Alan Saven
Cladribine in hairy cell leukemia.
Hematology/oncology clinics of North America 2006;20(5):1109-23.
2006: John R McWhirter; Anke Kretz-Rommel; Alan Saven; Toshiaki Maruyama; Kathleen N Potter; C Ian Mockridge; Edward Ravey; Fenghua Qin; Katherine S Bowdish
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(4):1041-6.
2005: Lyudmila Bazhenova; Emma Z Du; Sunil Bhoyrul; James McCallum; Alan Saven
Reactive thrombocytosis associated with a pheochromocytoma.
Thrombosis and haemostasis 2005;94(2):460-2.
2005: Armando V Mena-Duran; Summanuna H Togo; Lyudmila Bazhenova; José Cervera; Kelly Bethel; Maria L Senent; Jorge Nieva; Guillermo F Sanz; Miguel A Sanz; Alan Saven; Tomas Mustelin
SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor.
British journal of haematology 2005;129(6):791-4.
2004: Brunhilde Felding-Habermann; Richard A Lerner; Antonietta Lillo; Shufei Zhuang; Martin R Weber; Sandra Arrues; Changshou Gao; Shenlan Mao; Alan Saven; Kim D Janda
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(49):17210-5.
2004: Natalya Greyz; Alan Saven
Cladribine: from the bench to the bedside--focus on hairy cell leukemia.
Expert review of anticancer therapy 2004;4(5):745-57.
2004: Jorge Nieva; Alan Saven
Cladribine activity in systemic mast cell disease: application of biochemistry in the modern era of molecular biology.
Leukemia research 2004;28(2):113-4.
2003: Michael M Quigley; Kelly Bethel; Robert W Sharpe; Alan Saven
CD52 expression in hairy cell leukemia.
American journal of hematology 2003;74(4):227-30.
2003: Paul Wentworth; Jorge Nieva; Cindy Takeuchi; Roger Galve; Anita D Wentworth; Ralph B Dilley; Giacomo A DeLaria; Alan Saven; Bernard M Babior; Kim D Janda; Albert Eschenmoser; Richard A Lerner
Evidence for ozone formation in human atherosclerotic arteries.
Science (New York, N.Y.) 2003;302(5647):1053-6.
2003: Stephanie A Gregory; Delvyn C Case; Linda Bosserman; Debra L Litwak; William R Berry; Leonard A Kalman; Robert J Belt; Alan Saven
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Clinical lymphoma 2003;4(2):93-8.
2003: Melanie Rolli; Emilia Fransvea; Jan Pilch; Alan Saven; Brunhilde Felding-Habermann
Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(16):9482-7.
2003: Jorge Nieva; Kelly Bethel; Alan Saven
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Blood 2003;102(3):810-3.
2003: Grant R Goodman; Kelly Bethel; Alan Saven
Hairy cell leukemia: an update.
Current opinion in hematology 2003;10(4):258-66.
2003: Grant R Goodman; Ernest Beutler; Alan Saven
Cladribine in the treatment of hairy-cell leukaemia.
Best practice & research. Clinical haematology 2003;16(1):101-16.
2003: Grant R Goodman; Carol Burian; James A Koziol; Alan Saven
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(5):891-6.
2003: John C Byrd; B Peterson; Lawrence D Piro; Alan Saven; James W Vardiman; Richard A Larson; Charles Alan Schiffer
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Leukemia 2003;17(2):323-7.
2001: J Andrey; Alan Saven
Therapeutic advances in the treatment of hairy cell leukemia.
Leukemia research 2001;25(5):361-8.
2001: Brunhilde Felding-Habermann; Timothy E O'Toole; Jeffrey W Smith; Emilia Fransvea; Zaverio M Ruggeri; Mark H Ginsberg; Paul E Hughes; Nisar Pampori; Sanford J Shattil; Alan Saven; Barbara M Mueller
Integrin activation controls metastasis in human breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):1853-8.
2000: SA Tetreault; Alan Saven
Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia.
Leukemia & lymphoma 2000;37(1-2):125-30.
1999: SA Tetreault; B A Robbins; Alan Saven
Treatment of hairy cell leukemia-variant with cladribine.
Leukemia & lymphoma 1999;35(3-4):347-54.
1999: Alan Saven; Carol Burian
Cladribine activity in adult langerhans-cell histiocytosis.
Blood 1999;93(12):4125-30.
1999: Lawrence D Piro; Christine White; Antonio J Grillo-López; N Janakiraman; Alan Saven; T M Beck; CL Varns; S Shuey; Myron S Czuczman; J W Lynch; J E Kolitz; V Jain
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):655-61.
1999: Alan Saven; Carol Burian; J Adusumalli; James A Koziol
Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.
Blood 1999;93(8):2471-7.
1998: E S Liu; Carol Burian; William E Miller; Alan Saven
Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia.
British journal of haematology 1998;103(3):690-5.
1998: Alan Saven; Carol Burian; James A Koziol; Lawrence D Piro
Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Blood 1998;92(6):1918-26.
1997: R Gollard; William E Miller; Lawrence D Piro; Alan Saven
2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.
Leukemia & lymphoma 1997;28(1-2):183-5.
1997: Alan Saven; T Lee; M Schlutz; A Jacobs; D Ellison; R Longmire; Lawrence D Piro
Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):37-43.
1997: Barry Meisenberg; William E Miller; RL McMillan; M Callaghan; C Sloan; TL Brehm; M P Kosty; J Kroener; R Longmire; Alan Saven; Lawrence D Piro
Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):11-7.
1996: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
Hematology and cell therapy 1996;38 Suppl 2():S93-101.
1996: T C Lee; William E Miller; J G Curd; Lawrence D Piro; Alan Saven
Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.
Mayo Clinic proceedings. Mayo Clinic 1996;71(10):966-8.
1996: Alan Saven; T Lee; M Kosty; Lawrence D Piro
Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2139-44.
1996: M G Goodman; J C Spinosa; Alan Saven; Lawrence D Piro; Steven Wormsley
New perspectives on the approach to chronic lymphocytic leukemia.
Leukemia & lymphoma 1996;22(1-2):1-10.
1996: Alan Saven; W K Cheung; I Smith; M Moyer; T Johannsen; E Rose; R Gollard; M Kosty; William E Miller; Lawrence D Piro
Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):978-83.
1996: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine treatment of lymphoma.
Cancer treatment and research 1996;85():15-26.
1996: Alan Saven
The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia.
Seminars in hematology 1996;33(1 Suppl 1):28-33.
1996: R P Gollard; B A Robbins; Lawrence D Piro; Alan Saven
Acute myelogenous leukemia presenting with bulky lymphadenopathy. Case report and literature review.
Acta haematologica 1996;95(2):129-34.
1995: Alan Saven; S Emanuele; M Kosty; J Koziol; D Ellison; Lawrence D Piro
2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Blood 1995;86(5):1710-6.
1995: R Gollard; T C Lee; Lawrence D Piro; Alan Saven
The optimal management of hairy cell leukaemia.
Drugs 1995;49(6):921-31.
1995: Alan Saven; R H Lemon; M Kosty; E Beutler; Lawrence D Piro
2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):570-4.
1994: D J Ellison; R W Sharpe; B A Robbins; J C Spinosa; J D Leopard; Alan Saven; Lawrence D Piro
Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.
Blood 1994;84(12):4310-5.
1994: D A Hansen; B A Robbins; D J Bylund; Lawrence D Piro; Alan Saven; D J Ellison
Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia.
American journal of clinical pathology 1994;102(5):580-5.
1994: Alan Saven; K A Foon; Lawrence D Piro
2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis.
Annals of internal medicine 1994;121(6):430-2.
1994: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
The New England journal of medicine 1994;330(25):1829-30.
1994: Alan Saven; Lawrence D Piro; R H Lemon; M L Figueroa; M Kosty; D J Ellison; E Beutler
Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
Cancer 1994;73(12):2953-63.
1994: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies.
Annals of internal medicine 1994;120(9):784-91.
1994: CJ Carrera; Alan Saven; Lawrence D Piro
Purine metabolism of lymphocytes. Targets for chemotherapy drug development.
Hematology/oncology clinics of North America 1994;8(2):357-81.
1994: Alan Saven; Lawrence D Piro
Newer purine analogues for the treatment of hairy-cell leukemia.
The New England journal of medicine 1994;330(10):691-7.
1994: Lawrence D Piro; D J Ellison; Alan Saven
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.
Leukemia & lymphoma 1994;14 Suppl 1():121-5.
1993: Alan Saven; Lawrence D Piro
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
Cancer 1993;72(11 Suppl):3470-83.
1993: Alan Saven; M L Figueroa; Lawrence D Piro; Joseph D Rosenblatt
2-Chlorodeoxyadenosine to treat refractory histiocytosis X.
The New England journal of medicine 1993;329(10):734-5.
1993: Alan Saven; Lawrence D Piro
Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
Annals of internal medicine 1993;119(4):278-83.
1993: B A Robbins; D J Ellison; J C Spinosa; C A Carey; R J Lukes; S Poppema; Alan Saven; Lawrence D Piro
Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia.
Blood 1993;82(4):1277-87.
1993: Alan Saven; H Kawasaki; CJ Carrera; T Waltz; B Copeland; J Zyroff; M Kosty; D A Carson; E Beutler; Lawrence D Piro
2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):671-8.
1993: Alan Saven; R H Lemon; Lawrence D Piro
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
The New England journal of medicine 1993;328(11):812-3.
1993: H Kawasaki; CJ Carrera; Lawrence D Piro; Alan Saven; Thomas Kipps; Dennis A Carson
Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
Blood 1993;81(3):597-601.
1993: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia.
Cancer investigation 1993;11(5):559-64.
1993: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
Leukemia & lymphoma 1993;10 Suppl():43-9.
1993: Alan Saven; Lawrence D Piro
2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():109-14.
1993: Alan Saven; Lawrence D Piro; CJ Carrera; D A Carson; E Beutler
Hairy cell leukemia: new understanding of biology and treatment.
Cancer treatment and research 1993;64():15-34.
1992: Ari Zimran; A Kay; Terri Gelbart; P Garver; D Thurston; Alan Saven; E Beutler
Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients.
Medicine 1992;71(6):337-53.
1992: Alan Saven; CJ Carrera; D A Carson; E Beutler; Lawrence D Piro
2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
Blood 1992;80(3):587-92.
1992: Alan Saven; Lawrence D Piro
Treatment of hairy cell leukemia.
Blood 1992;79(5):1111-20.
1992: A C Kay; Alan Saven; CJ Carrera; D A Carson; D Thurston; E Beutler; Lawrence D Piro
2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):371-7.
1991: E Beutler; A Kay; Alan Saven; P Garver; D Thurston; A Dawson; B Rosenbloom
Enzyme replacement therapy for Gaucher disease.
Blood 1991;78(5):1183-9.
1991: A C Kay; Alan Saven; P Garver; D W Thurston; B F Rosenbloom; E Beutler
Enzyme replacement therapy in type I Gaucher disease.
Transactions of the Association of American Physicians 1991;104():258-64.
1991: CJ Carrera; Lawrence D Piro; Alan Saven; E Beutler; C Terai; Dennis A Carson
2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes.
Advances in experimental medicine and biology 1991;309A():15-8.
1990: E Beutler; Alan Saven
Misuse of marrow examination in the diagnosis of Gaucher disease.
Blood 1990;76(3):646-8.